Medicare Expands Obesity Drug Coverage, but Most Seniors Remain Unaware

Starting this week, eligible Medicare beneficiaries can access obesity medications through Medicare's new Bridge demonstration program, paying a monthly copay of $50. The initiative represents a significant policy shift, giving millions of older Americans access to weight-loss therapies from companies such as Novo Nordisk and Eli Lilly that were previously unavailable to many Medicare recipients.

Despite the landmark expansion, public awareness remains low. A recent survey by the Obesity Care Advocacy Network found that 82% of Americans aged 65 and older were unaware that Medicare would begin covering obesity drugs. The lack of awareness spans political affiliations, suggesting that many eligible patients may not immediately benefit from the new program.

Unlike traditional Medicare drug coverage, enrollment in the Bridge program requires several additional steps. Patients must meet eligibility criteria, obtain a physician's prescription, and receive prior authorization from the Centers for Medicare & Medicaid Services (CMS) before coverage becomes effective, making the rollout more complex than a standard benefit expansion.

Healthcare experts say limited public communication ahead of the launch may slow adoption. While CMS has conducted extensive outreach to physicians and pharmacists, some specialists believe many seniors have received little direct information about the program, potentially delaying appointments and prescriptions for eligible patients.

The relatively quiet rollout contrasts sharply with the extensive marketing campaigns that Novo Nordisk and Eli Lilly have historically used for their obesity and diabetes medications. Industry analysts noted that the companies have previously invested hundreds of millions of dollars in consumer advertising, yet promotion surrounding the Medicare expansion has so far remained relatively modest.

Both CMS and drug manufacturers suggest the gradual approach is intentional. Officials said public awareness campaigns are expected to increase now that coverage is officially available, while pharmaceutical companies emphasized the importance of preparing healthcare providers and pharmacies before generating widespread consumer demand.

The program's eligibility is broad but not universal. Medicare beneficiaries must be enrolled in a Part D prescription drug plan, while patients already receiving GLP-1 medications through Medicare for approved conditions such as Type 2 diabetes, cardiovascular risk reduction, or sleep apnea are generally not eligible for additional coverage under the Bridge program.

Novo Nordisk said it has begun promoting the program through its website and social media channels, while Eli Lilly indicated broader marketing efforts are expected in the coming months. Company executives believe pharmacies and healthcare providers will play a central role in educating patients, as older adults frequently interact with pharmacists when managing multiple prescriptions.

Medical experts also believe the phased rollout could help prevent operational bottlenecks. Processing prior authorization requests for millions of potential beneficiaries may take time, and a gradual increase in demand would allow CMS, healthcare providers, and pharmacies to refine procedures before patient volumes rise significantly.

The new coverage marks an important milestone in obesity treatment under Medicare. However, its overall success will depend not only on expanded access but also on effective patient education, provider readiness, and the healthcare system's ability to manage what could become one of Medicare's largest new prescription drug programs in recent years.